Video

Urology Times 50 Innovations Series: β3 agonists for overactive bladder

Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Ekene A. Enemchukwu, MD, MPH, discusses the development of β3 agonists for the treatment of overactive bladder (OAB). Enemchukwu is an assistant professor of urology and, by courtesy, of obstetrics and gynecology and medical director of the Stanford Pelvic Health Center, Stanford University, Palo Alto, California

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Vanita Gaglani, RPT, answers a question during a video interview
William Furuyama, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman talking with doctor | Image Credit: © LuneVA/peopleimages.com - stock.adobe.com
Vanita Gaglani, RPT, answers a question during a video interview
Raveen Syan, MD, FPMRS, answers a question during a video interview
Jaspreet S. Sandhu, MD, answers a question during a video interview
Anne Pelletier Cameron, MD, FRCSC, FPMRS, answers a question during a video interview
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
© 2025 MJH Life Sciences

All rights reserved.